Chardan Capital Lowers Spark Therapeutics (ONCE) Price Target to $60.00
Spark Therapeutics (NASDAQ:ONCE) had its target price reduced by investment analysts at Chardan Capital from $100.00 to $60.00 in a research note issued to investors on Tuesday. The firm currently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price target indicates a potential upside of 32.58% from the stock’s current price.
A number of other analysts have also commented on the company. BMO Capital Markets set a $73.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a report on Tuesday. Leerink Swann lowered Spark Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday. UBS lowered Spark Therapeutics from a “buy” rating to a “neutral” rating and set a $51.00 target price for the company. in a report on Tuesday. Cantor Fitzgerald set a $105.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a report on Monday. Finally, Raymond James Financial reissued a “buy” rating and issued a $75.00 target price on shares of Spark Therapeutics in a report on Thursday, December 7th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $83.75.
Spark Therapeutics (NASDAQ ONCE) traded down $2.46 during mid-day trading on Tuesday, reaching $45.26. The company had a trading volume of 1,613,121 shares, compared to its average volume of 459,444. Spark Therapeutics has a one year low of $41.06 and a one year high of $91.75.
In other news, CFO Stephen W. Webster sold 10,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $70.14, for a total value of $701,400.00. Following the transaction, the chief financial officer now directly owns 12,500 shares in the company, valued at approximately $876,750. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Katherine A. High sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total value of $356,600.00. Following the completion of the transaction, the insider now owns 215,000 shares in the company, valued at $15,333,800. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,068,809 shares of company stock worth $89,809,385. Company insiders own 7.30% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in shares of Spark Therapeutics by 15.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after buying an additional 241,016 shares during the last quarter. BlackRock Inc. lifted its position in Spark Therapeutics by 11.6% during the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after purchasing an additional 213,520 shares in the last quarter. Amundi Pioneer Asset Management Inc. purchased a new position in Spark Therapeutics during the third quarter valued at $5,286,000. TIAA CREF Investment Management LLC lifted its position in Spark Therapeutics by 20.3% during the second quarter. TIAA CREF Investment Management LLC now owns 62,480 shares of the biotechnology company’s stock valued at $3,733,000 after purchasing an additional 10,544 shares in the last quarter. Finally, Balyasny Asset Management LLC lifted its position in Spark Therapeutics by 104.8% during the second quarter. Balyasny Asset Management LLC now owns 59,400 shares of the biotechnology company’s stock valued at $3,549,000 after purchasing an additional 30,400 shares in the last quarter. Hedge funds and other institutional investors own 94.94% of the company’s stock.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.